Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 56, Issue 14, Pages 5675-5690Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm400402q
Keywords
-
Categories
Ask authors/readers for more resources
The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available